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IN this experiment living Ehrlich ascites carcinoma was combined with
Freund's adjuvant in an attempt to induce immunity to the tumour. This
adjuvant has been shown to enhance antibody production and to produce a
specific allergic type response to hetero-, homo-, and autotransplants (Freund,
1956; Witebsky, Rose, Paine and Egan, 1957; McMaster, Lerner and Exum,
1961). Both serum antibodies and delayed sensitivity have been reported
following its use (Freund, 1956). Medawar (1948) has shown that delayed
sensitivity is involved in the rejection oftissue transplants, and it is also involved
in the rejection of tumour transplants (Lawrence, 1956).
It has been shown that a combination of dead tumour in Freund's adjuvant
may result in the production of tumour antibodies (Fink, Smith and Rothlauf,
1955; Witebsky, Rose and Shulman, 1956; Graham and Graham, 1959; Finney,
Byers and Wilson, 1960), but these are not easy to demonstrate. In the present
experiment living tumour was used to avoid the possibility of denaturating the
tumour protein, and subcutaneous injection was chosen as it is thought to be
optimal for the development of delayed sensitivity (Lawrence, 1956). The blood
content of the tumour ascites was used as a measure of the tumour immunity
(Hartveit, 1961b).
MATERIAL AND METHODS
Jlice.-These were similar to the mice used in previous experiments (Hartveit,
1961b) and were selected in the same way. Eight groups of 15 males and 15
females were set up.
Tumour.-The Ehrlich ascites carcinoma used was taken from the 84th
transplant generation of the tumour maintained at this Institute.
Preparation of the adjuvant.-Freund's method (1956) for the preparation of
complete adjuvant was followed. Eucerin anhydrous was used as the emulsify-
ing agent. Thetubercle bacilli wereofstrain H37, Rv (kindlysuppliedbyProfessor
Vogelsang, Gade Institute, Department of Microbiology). Four ml. of this adju-
vant mixture were emulsified with 4 ml. of saline.
Preparation of tumour inoculum.-The tumour ascites from two male and two
female mice that had been injected intraperitoneally with Ehrlich's ascites
carcinoma 10 days previously, was pooled. The resulting fluid contained 2,110,000
tumour cells/mm3 ; PCV 31 per cent, and 1 per cent packed erythrocytes. All
the tumour cells were considered viable as none stained by Schrek's method (1936).
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further quantity was diluted with saline to give the same tumour cell dose/unit
volume as in the tumour-adjuvant mixture. The remaining fluid was used
undiluted.
Experimental procedure.-The treatment given to the mice is summarized in
Table I. The intraperitoneal tumour dose was 0.1 ml. The subcutaneous
injections (0.05 ml.) were given on the back. When the injections had been
completed only an occasional tumour cell in the remaining fluid was of doubtful
viability.
TABLE I.-The Treatment given to the Mice in the Different Groups.
(EAC _ Ehrlich's ascites carcioma. FA = Freund's adjuvant)
Route of injection
Group Subcutaneous Intraperitoneal
1 . nil nil
2 nil EAC
3 FA + EAC nil
4 . FA + saline nil
5 EAC + saline nil
6 . FA + EAC EAC
7 FA + saline EAC
8 EAC + saline EAC
Thereafter any subcutaneous growths were measured weekly. When a
mouse died the survival time was recorded in days. If a subcutaneous growth
was present this was measured. If the mouse had been given an intraperitoneal
injection 1 ml. of the ascites was centrifuged and the PCV of the erythrocytes
recorded (Hartveit, 1961a).
RESULTS
Survival time.-Table II gives the mean survival time of the mice that
received intraperitoneal tumour. The differences between the groups are not
significant for the total or male series. The females in groups 6 and 7 died
significantlyearlierthanthosein group 8 (0.05 > P > 0-02 and 0 01 > P > 0-001,
respectively). The females in group 7 also died earlier than the males in the same
group (0.01 > P > 0.001). The sex difference in the other 3 groups is not
statistically significant.
All the mice in the remaining control groups were alive a week after the last
mouse with intraperitoneal tumour died; showing that the mice themselves and
their surroundings were healthy, and that the subcutaneous treatment did not
kill the mice within the time limit of the experiment. The survival times of
these animals will be discussed in a later paper.
TABLE II.-The Mean Survival Time (with SD) of the Mice in the Groups with
Intraperitoneal Tumour. (30 mice in each group)
Mean survival time (days)
Group Total series Male series Female series
2 . 12-8 ±2-944 13*86+ 3178 11*73± 2220
6 . 11-7 ±3-435 12-8 ±3-661 10*6 +2846
7 11.93i 2497 13-26+ 2-657 10-6 i1e342
8 . 12-9 + 1 817 13-06 i 1-378 12-73 ± 2*168
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The blood content of the tumour ascites.-This was measured in groups 2, 6, 7
and 8, and the mean percentages are shown in Table III. The greatest amount of
blood was present in group 6. Groups 2 and 7 showed approximately the same
amount for the total series, while group 8 showed least. The difference between
groups 6 and 8 is significant for the total and female series (0.01 > P > 0 001 and
0*02 > P > 0 01, respectively). The sex difference was only significant in group
7 in which the males showed less blood than the females (0 001 > P). As a
result ofthis the difference in blood content between the males in groups 6 and 7
becomes significant (0.05 > P > 0.02).
TABLE III.-The Mean Blood Content of the Ascites (with SD) in the Mice with
Intraperitoneal Tumour. (30 mice in each group)
Mean blood content (per cent)
Group Total series Male series Female series
2 5-1 + 2-902 4-26 + 2*755 5-93 ± 2-795
6 . 6-931± 4-842 6-0 ± 4957 7 8 4-564
7 . 5-0 2-532 3-071± 1-594 6-8 1-797
8 . 3-86 ± 2-565 3-4 2-184 4*3 ± 2-802
The results in male groups 6 and 7 are based on 14 mice as too
little ascites was present in the remaining two.
The correlation between the survival time and the blood content of the ascites
(groups 2, 6, 7 and 8).-Table IV shows that this negative correlation is highest
in the control group 2 (0.001 > P), and next highest in group 6 (0 001 > P), the
experimental group. It is statistically significant in all groups but group 7.
TABLE IV.-Correlation Between Survival Time and Blood Content of the Ascites
in Mice with Intraperitoneal Tumour. (30 mice in each group)
Correlation coefficient (r)
Group Total series Male series Female series
2 . -0-8383 -0 8774 -0 7700
(0*001> P) (0-01 > P > 0-001) (0-02 > P > 0-01)
6 -0-7905 -0-7900 -0*7844
(0-001 > P) (0-02 > P > 0-01) (0-02 > P > 0.01)
7 . -0-6195 -0-2505 -0-5542
(0. 0l>P>0-001) (0-4>P>0-3) (0-1>P>0-5)
8 -0 6653 -0 7638 -0-5981
(0-01> P > 0-001) (0-02 > P > 0-01) (0*05 > P > 0 02)
Results based on 14 male mice in groups 6 and 7.
For the purposes of the following calculations the mean survival time of the
animals in group 2 (12.8 days) was taken as the dividing line between those with a
short (a) and those with a long (b) survival time following intraperitoneal injection
of the tumour.
The distribution ofthe survival time ofthe mice within the groups (2, 6, 7 and 8).-
Table V shows that the mice in groups 2 and 8 were more or less evenly distributed
between groups a and b, while group 7 showed more, and group 6 even more, mice
in group a. In groups 2 and 8 the sex difference in this distribution is not signi-
325F. HARTVEIT
ficant, while it is so in groups 6 and 7 (0.01 > P > 0.001) as many more females
than males fall into group a. For the total series the difference in the percentage
ofmice in group aissignificant betweengroups 6 and 8, and forthefemalesbetween
groups 6 and 8 (0 01 > P > 0.001) and 7 and 8 (0.05 > P > 0.02).
TABLE V.-The Distribution of the Survival Time of the Mice with Intraperitoneal
Tumour within the Groups, giving Number of Mice (per cent)
Survival time
Short (a) Long (b)
Group Male Female Total Male Female Total
2 . 5 10 15 (50) 10 5 15 (50)
6 . 7 14 21 (72.4) 7 1 8 (27 6)
7 . 5 13 18 (62-1) 9 2 11 (37 9)
8 6 8 14 (46 7) 9 7 16 (53.3)
The results in male groups 6 and 7 are based on 14 instead of 15 mice as
the ascites in the remaining two was not suitable for further investigation.
The distribution of the mean blood content ofthe tumour ascites (per cent) according
to the survival time within the groups (2, 6, 7 and 8).-Table VI shows that in all
cases there was more blood in group a than b. This difference was statistically
significant in all groups. The sex difference within the groups was significant in
group 7a (0.001 > P), and in group 6b (but the latter contains only one female
mouse). For the total series the difference between groups 6a and 8a is significant
(0 01 > P > 0.001), for the male series that between groups 6a and 7a, and for
the females those between groups 2b and 6b and 2b and 8b (0.05 > P > 0.02).
TABLE VI.-The Distribution of the Mean Blood Content of the Tumour (per cent),
with SD, according to the Survival Time within the Groups of Mice with
Intraperitoneal Tumour. (30 mice in each group)
Survival time
Short (a) Long (b)
r r
,A
Group Male Female Total Male Female Total
2 . 6-8 ±3-763 6-9 +2-468 6-86±3-891 3 0 ±1-673 4 0 +2-408 3.3 +2-037
6 8-7 ±5-719 8-36±4-201 8-47±4-659 3-29±1-375 0-0 ±0-0 2-9 ±1-458
7 3-4 ±1-908 7-23±1-480 6-17±4-078 2-89±1-485 4 0 ±1 0 3-09±1-475
8 4-0 ±1-965 5-62±2-287 5 0 ±2-3 2-89±5-509 2-86+2-641 2-88+2-367
The results in male groups 6 and 7 are based on 14 mice as too little ascites was present in the
remaining two.
The subcutaneous injection site.-This was examined in all appropriate groups
on the 7th day after injection. The findings are shown in Table VII. The three
mice in group 6 that had died by this time showed thickening under the skin at
the injection site, but no palpable masses. The differences in mean tumour
diameter between groups 3, 5 and 8 are not statistically significant. Thus the
addition of adjuvant to the tumour has not affected its vitality. The difference
between groups 3 and 6 (Fig. 1), is significant (0.001 > P). The sex difference
is only significant in group 5 in which the tumours in the males were larger than
those in the females (0.05 > P > 0.02).
326IMMUNITY TO EHRLICH S ASCITES CARCINOMA
2-
a
E
0
1
t 3 45 67 9 011 2 3 14 5 12 3456 10 11 12 1Z3 14
Mouse number
-----Males Females
FIe.. I.-Greatest subcutaneous tumour diameter 7 days after injection in group 3 (hatched
columns) and group 6 (dark columns). Values for individual mice in each group given alter-
nately. Note: The tumours were measured at autopsy in 3 mice in group 6.
TABLE VII.-The, Average Greatest Diameter (mm) of the Subcutaneous Tumours
(with SD) at 7 Days
Tumour diameter SD
Group (mm.) (mm.)
3 . 9-73 . 2-112
5 . 9* 166 . 3-976
6 . 1-4 . 1-698
8 . 7*13 . 4-249
All the mice that had been given adjuvant without tumour subcutaneously
(groups 4 and 7) showed slight thickening at the injection site on the 7th day.
At 14 days in group 4, and at 14 days or at autopsy in group 7, the site was
difficult to locate in the males while all the females showed a distinct freely
movable swelling (approximately 0-5 cm. in diameter) in the subcutaneous tissues.
Ulceration did not occur.
DISCUSSION
The majority of attempts to detect serum antibody to tumour tissue have
failed (Barrett, 1958) and some of the serum antibodies that have been reported
(Southam, 1960) may have been due to genetic differences between host and tum-
our and not to the fact that the tissue was tumour tissue. For there to be a
genetic difference between a host and its own tumour a. mutation must have
occurred. The mutation, in altering the function of the mutant gene (Oglinsky
and Umbreit, 1959), may result in a change in the protein synthesised. This
protein may then be recognized as " non-self": a change in a surface protein
producing serum antibody, one deep in the cell giving delayed sensitivity. But
if the mutation results in a change in the rate of protein synthesis leaving the
structure unchanged (Brinkhaus and Graham, 1954; Pitney and Elliott, 1960),
no recognition can be expected. This, or a change in an intracellular protein,
could explain the almost universal failure to detect serum antibody to autologous
tumours. In the former case any enhancing action shown by Freund's adjuvant
could be due to the mobilization of immunologically active cells (Burnet, 1959).
In the latter some factor in the adjuvant may combine with the " self " protein,
the combination beingrecognizedimmunologically (Freund, 1956). Suchhaptene
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formation is thought to occur in the autoimmune diseases (Favour, 1956; Voisin,
Toullet and Maurer, 1958; Asherson and Broberger, 1961).
In reactions involving normal autologous tissues the second mode of action
must be postulated as the possibility of genetic difference does not exist. While
reaction against the protein-haptene complex could be expected, reaction against
the original protein has, in fact, been demonstrated (McMaster, Lerner and Exum,
1961). Thus, it is not necessary to postulate a genetic difference between host
and tumour to explain the rationale of using a combination ofautologous tumour
and Freund's adjuvant in an attempt to produce changes in a distant transplant
ofthe tumour.
While the tumour used in this experiment is a homograft it is known that
some of the mice used will accept it as an autograft, the blood content of the
tumour ascites being a measure of their natural immunity (Hartveit, 1961b).
The present experiment was designed to see if subcutaneous treatment with
Freund's adjuvant combined with living tumour would increase the immuno-
logical response ofthe mice to the tumour and, ifthis were so, whether the increase
was in natural or acquired resistance. To show this the distribution of the mice
within the groups was investigated. The mean survival time of the animals in
the control group 2 was taken as the dividing line between those with a short (a)
and those with a long survival time (b); the mice in group a being those resisting
the tumour, group b accepting it. If the treatment resulted in a greater number
of mice in group a than could be expected on the basis of the findings in the con-
trols-it would then have been shown that immunity had been induced in some
of the mice that would normally have accepted the tumour without response.
The results show that the mice in group 8 had the longest survival time, the
least blood in the tumour ascites and the highest number of mice in group b.
Thus these mice show most evidence of accepting the tumour homograft, even
more than the untreated control group 2. This may be an example of an XYZ
effect (Casey, Hatherway and Casey, 1956; Goldie, Walker, Kelley and Gaines,
1956) brought about through a decrease in the immunological response of the
host. This is in keeping with clinical experience of malignant growths (Graham
and Graham, 1955). As the mice in this group show least evidence of natural
immunity they are, in fact, more suitable than group 2 as a control for the
experimental group 6.
The following differences between group 6 and 8 are statistically significant.
The females in group 6 died earlier than those in 8. There was more blood in the
ascites in group 6 than in group 8. Group 6 showed a higher percentage of mice
in group a than did group 8, and there was a higher blood content in the ascites
in 6a than 8a.
These results consistently indicate that the subcutaneous tuniour-adjuvant
mixture increased the immunological response of the mice to the intraperitoneal
tumour. The effect is particularly marked in the females in group 6 only one of
which remained in group b, i.e. was unaffected by the adjuvant-antigen mixture.
The increase in the tumour blood content shows that the immunity of the mice
which already possess some natural resistance has been strengthened. The
increase in the number of mice in group a shows that immunity has been induced
in some mice that previously lacked resistance. As it has proved possible to
measure both natural and acquired immunity through the blood content of the
tumour it is probable that the same mechanism is at work in both cases.
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As the mice in group 7 received adjuvant alone subcutaneously the decrease
in survival time and increase in tumour blood content in the female mice must
be regarded as non-specific. Non-specific allergic responses have been reported
with normal tissues following the injection of adjuvant alone (Voisin, Toullet and
Maurer, 1958), but a marked sex difference has not been described previously.
This sex difference is further reflected in the reaction at the subcutaneous injection
site, which was marked in the females and absent in the males. As the findings in
group 4 were similar the reaction is not dependent on the presence of intraperito-
neal tumour. It is often easier to produce specific tumour immunity in female
mice (Gross, 1943) as is shown in group 6. It appears that non-specific immunity
also is easier to produce in females.
This non-specific immunity must differ in some way from that produced by
adjuvant combined with antigen as the normal relationship between the survival
time and the tumour blood content, that holds in group 6, has been upset in
group 7. It may be that the mode of action of adjuvant alone differs from that
of an adjuvant-antigen mixture. Wrhile the adjuvant alone will be able to mobi-
lize immunologically active cells, haptene formation will not be possible. This
strengthens the idea that haptene formation is concerned in the adjuvant-antigen
response to tumour tissue.
It was also found that in mice with intraperitoneal tumour, the tumour in the
adjuvant-antigen mixture failed to grow as quickly as in the mice without a
further source of tumour (Table VII and Fig. 1). This is contrary to what would
be expected on the basis of an XYZ effect, and is difficult to explain. It may be
that the intraperitoneal tumour stimulates the sensitivity reaction by neutralizing
its products.
SUMMARY
Freund's adjuvant given subcutaneously in combination with living Ehrlich
ascites carcinoma was found to increase the immune response of mice to the
intraperitoneal injection of the same tumour. Both natural and acquired im-
munity appear to have been affected. An increase in the immune response was
also found in female mice following Freund's adjuvant alone. Evidence is
presented that the mechanism of this non-specific reaction differed from that of
the specific reaction. The combination of adjuvant and living tumour had an
inhibitory effect on the growth of the tumour in the adjuvant mixture when
intraperitoneal tumour was also present.
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